The Catalan biotechnological company Iproteos, spin-off of the University of Barcelona and the Institute for Research in Biomedicine (IRB Barcelona), advised by Bosch Gimpera Foundation (FBG) and with headquartered at the Barcelona Science Park (PCB), has received a loan of €150,000 by the IFEM to continue its activity main R & D of new drugs to develop proprietary technologies IPRO (IPROTech) to promote international expansion and marketing.
The loan of the IFEM will enhance the advancement of the development of this drug to market as soon as possible.
Iproteos applied successfully IPROTech their internal projects dedicated to schizophrenia and epilepsy.
The drug has improved working memory, attention, cognitive flexibility and motivation, among others, in animals with schizophrenia.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Proceeds to support clinical development of lead first-in-class progra...
